Page 2 - Menu Hover News Today

Sanofi has announced a collaboration with investment management firm Blackstone to advance an innovative treatment for multiple myeloma.

The US Food and Drug Administration (FDA) has declined to grant approval for Gilead Sciences’ investigational therapy lenacapavir for HIV.

ViiV Healthcare has secured the US FDA approval for the expanded labelling of Cabenuva (cabotegravir, rilpivirine) to treat HIV-1 in adults.

Biotechnology firm Neogene Therapeutics has signed an exclusive, global license agreement with the National Cancer Institute (NCI) for a portfolio of T cell receptor (TCRs) targeting KRAS and TP53 mutations for the treatment of patients suffering with cancer.

Abbvie has submitted applications to the US FDA and the EMA to obtain approvals for upadacitinib (RINVOQ) to treat nr-axSpA.

Inovio has secured approval from Center for Drug Evaluation of the National Medical Products Administration in China to carry out two clinical trials of heterologous prime-boosting with its Covid-19 vaccine candidate, INO-4800.

At its meeting yesterday, the Supervisory Board of Gerresheimer AG extended the contract with CEO Dietmar Siemssen to the end of October 2026. Dietmar Siemssen has been CEO

Roche has secured breakthrough therapy designation from the US FDA for tiragolumab plus Tecentriq as a first-line treatment for people with NSCLC whose